Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Cancer Vaccine
Treatment p19(Arf)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature CCL2
Official Symbol CCL2
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Bead array analysis revealed in both the IFN-β and the combination groups an increase in cytokines associated with a TH1 immune response (IL-12, IL-6, TNF-α, IFN-γ, MCP1/CCL2), and with the exception of IL-10, no alteration was seen in the TH2 and TH17 profile.
PMID 26887933
Title Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.